Integra LifeSciences (NASDAQ:IART) Releases FY 2026 Earnings Guidance

Key Points

• Integra LifeSciences lowered its FY 2026 outlook, forecasting EPS of $2.30–$2.40 versus the $2.46 analyst consensus, with revenue guidance of $1.6 billion–$1.7 billion. Q3 2026 EPS guidance was set at $0.55–$0.59.
• The company’s latest quarterly results exceeded expectations, with EPS of $0.56 versus the $0.48 consensus and revenue of $418.76 million compared with estimates of $417.54 million.
• Shares opened at $16.09, down 1.2%, while analysts maintained a generally cautious view: the stock has a consensus “Reduce” rating and an average price target of $18.86.

Integra LifeSciences (NASDAQ:IART - Get Free Report) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 2.300-2.400 for the period, compared to the consensus EPS estimate of 2.460. The company issued revenue guidance of $1.6 billion-$1.7 billion. Integra LifeSciences also updated its Q3 2026 guidance to 0.550-0.590 EPS.

Integra LifeSciences Stock Down 1.2%

Shares of IART opened at $16.09 on Friday. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $20.49. The firm's 50 day moving average is $16.83 and its 200-day moving average is $15.17. The stock has a market capitalization of $1.25 billion, a PE ratio of -178.76, a P/E/G ratio of 0.84 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The business had revenue of $418.76 million during the quarter, compared to analysts' expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Equities research analysts forecast that Integra LifeSciences will post 2.46 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on IART shares. Weiss Ratings upgraded Integra LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 14th. Truist Financial raised shares of Integra LifeSciences to a "hold" rating in a research report on Thursday. Wells Fargo & Company raised their target price on shares of Integra LifeSciences from $15.00 to $18.00 and gave the company an "equal weight" rating in a report on Thursday, July 30th. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They issued a "market perform" rating and a $19.00 target price for the company. Finally, Citigroup reaffirmed a "neutral" rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Integra LifeSciences currently has an average rating of "Reduce" and a consensus price target of $18.86.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company's products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.